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1. Introduction 
The H19-IGF2 locus within the imprinted cluster of the human chromosome 11, has been 
implicated in a variety of disorders and cancer pre-disposition including bladder cancer. 
BBN induced bladder cancer model in rats has identified both H19 and IGF2 among 
differentially expressed genes that are induced in response to carcinogen exposure.  
In this chapter, the role of both H19 and IGF2 genes in cancer will be handled in general 
with special focus on bladder cancer. Although IGF2 role in human cancers is relatively well 
established, recent data from our laboratory and others have just revealed a critical role for 
H19 RNA in the process of tumorigenicity including that of the bladder.  H19 functions as a 
stress modulator, being induced by hypoxia, and a survival factor that is involved in several 
fundamental processes of tumorigenesis. Furthermore, we uncovered a molecular 
mechanism that integrates H19, p53 and HIF1-┙ to hypoxic stress response. Placing the H19 
gene product in this deadly circuit undoubtedly will have major impacts in its utility as a 
target for cancer gene therapy. 
Regulatory sequences of both H19 and IGF2 have already been used to successfully target 
expression of a toxic protein, diphtheria toxin A (DT-A), in carcinoma cells in culture, in 
several xenograft, orthotopic animal models, and in chemically induced BBN model of 
bladder cancer. In case of H19, it is successfully used in patients with bladder carcinoma for 
a period of over 5 years and recently a clinical trial phase I/IIa using this therapeutic 
approach has been successfully completed. It is also successfully used in other types of 
human cancers but will not be handled in the current chapter. 
We will discuss also novel approaches, to create a new family of plasmids. In one approach 
a cytotoxic gene is driven by two different regulatory sequences, selected from the cancer-
specific promoters H19, IGF2-P3 and IGF2-P4 carried on a single construct. In a second 
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approach a single promoter is used to drive two cytotoxic genes having synergistic effect on 
a single construct. Both approaches show superior tumor growth inhibition activity, in 
preclinical studies of bladder cancer. 
Bladder Cancer is the fourth most common cancer in men accounting for about 7% of all 
cancer cases and 3% of all cancer related mortality. Each year, more than 50,000 new patients 
are diagnosed with bladder cancer in the USA and about 10,000 die from this disease (Jemal 
et al., 2010). Carcinogens activity on a susceptible epithelium is believed to be the cause of 
bladder cancer. Many industrialized chemicals are causally related; benzidine, 
┚napthylamine, 4-aminobiphenyl, etc. However, the commonest cause of bladder cancer 
nowadays, is by far cigarette smoking accounting for about half of all bladder cancers 
(Burch et al., 1989). Whether bladder cancer arises from a single transformed cell (clonogenic 
theory) or from multiple transformed cells (field change theory),  is still under debate.  
Painless hematuria is the hallmark of bladder cancer. This dramatic symptom urgently 
brings the patient to see a doctor. Therefore, most bladder tumors are diagnosed during the 
lifetime of the patient. Bladder tumors can also present with irritative urinary symptoms 
(urinary urgency, frequency and dysuria). Bladder tumors can be diagnosed by 
ultrasonography, intravenous urography, or computerized tomography. The resolution of 
these radiologic techniques is low, and only a 5 to 10 mm lesion can be detected. Cystoscopy 
done by inserting an optical instrument into the bladder can diagnose bladder tumors as 
small as 1mm. Urinary cytology is an important adjunct to cystoscopy, especially for the 
diagnosis of the flat lesion carcinoma in-situ (CIS). 
Most bladder tumors arise from the epithelial lining the urinary system-the transitional 
epithelium (urothelium), and are therefore, transitional cell carcinomas (or urothelial 
carcinomas). Bladder cancer is a heterogeneous disease with wide variations in molecular 
pathogenesis, morphology and prognosis. They are classified according to their depth of 
invasion into the bladder wall (stage) and according to the degree of histological anaplasia 
(grade). 
As in most other types of cancer, it is believed that 4-6 DNA hits are required for malignant 
transformation (Duggan et al., 2004). These include deletions, mutations and loss of 
heterozygosity (LOH) of genetic material that carries tumor suppressor genes or proto-
oncogenes, and epigenetic changes such as CpG methylations that modify gene expression. 
There are at least 2 major pathogenic pathways leading to 2 completely different bladder 
cancers. One pathway leads a low grade, papillary bladder cancer (about 75% of all bladder 
tumors). This type of tumor has a proliferative ability but no ability to invade the epithelial 
lamina propria and muscle of the bladder, to metastasize and to kill the patient. The second 
pathway leads to a high grade, solid tumor that has an invasive and metastatic potential 
(about 15% of the tumors). Possibly, there is a third pathway that leads to a high grade 
papillary tumor (about 10% of the tumors) (Goebell &Knowles, 2010). While low grade 
tumors tend to recur but almost never endanger the life of the patient, high grade tumors 
are often lethal.  
It is believed that low grade tumors develop following this pathway: Urothelial 
hyperplasia urothelial atypia low grade TCC. The most prominent molecular change in 
this group is mutation in FGFR3, found up to 88% of these tumors (van Rhijn et al., 2002). In 
most cases these are activation mutation that probably supports tumor proliferation by 
stimulating the RAS-MAPK pathway. The frequency of FGFR3 mutations in high grade 
tumors is much lower. Activation of the phosphatidylinositol 3–kinase (PI3K) pathway by a 
wide range of mechanisms is also typical to low grade tumors (Goebell &Knowles, 2010). 
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High grade bladder tumors develop following this pathway: Urothelial atypia dysplasia 
 CIS Invasive TCCmetastatic disease. The most prominent molecular changes in high 
grade tumors involve inactivation of the p53 and RB pathways. p53, whose activity is 
augmented in the presence of DNA damage, arrests cells at G1-S checkpoint by inducing the 
transcription of the CDK inhibitors-p21/Waf1, and GADD45. Then the cell may either 
correctly repair its DNA or undergo apoptosis. Deletions or mutations in the p53 pathway 
are found in about 70% of the high-grade tumors. 
The Retinoblastoma gene codes for an 110kDa nuclear phosphoprotein acting as a tumor 
suppressor that also arrest cells at G1. It is often mutated by a truncating mutation of the 
carboxyl terminal. Mutations or deletions in Rb gene are found in 30% of the patients with 
advanced bladder cancers. They result in uncontrolled cellular proliferation even without 
mitogenic signals. Hypermethylation of the Rb promoter region can have the same effect. 
Similarly, loss of the cyclin dependent kinase inhibitor p16 either by mutation, deletion, or 
by promoter hypermethylation, as documented in 20-45% of the bladder cancers prevents 
Rb activation by hyper-phosphorylation, or leads to uncontrolled cell cycle progression 
(Schultz, 1998). 
Epithelial to mesenchymal transition (EMT) is an important process typical to high grade 
tumors. It is characterized by down regulation of the adhesion molecule E-cadherin and of 
proteins associated with cell polarity along with up regulation of fibronectin, vimentin and 
matrix metalloproteases (MMPS). EMT is induced by cytokines like the TGF┚ and is 
associated with increased invasion, migration and angiogenesis.  
Alterations in chromosome 9 are the most common cytogenetic findings in bladder cancer. 
Of these, the most common are deletions and LOH in the short arm, home of the tumor 
suppressor genes and cell-cycle regulators CDKN2A (encoding for p16 and p14ARF) and 
CDKN2B (encoding for p15).  In a rather consistent manner high grade tumors demonstrate 
LOH of 3p, 8p, 13q, and 17p, while low grade tumors demonstrate LOH of chromosome 9 
only (Knowles et al., 2001). 
Animal models are critical in the understanding of bladder cancer pathogenesis and in the 
quest for new treatments.  Most animal models in bladder cancer are in rodents. Although 
various models exist, we'll focus on carcinogen induced bladder cancer model. 
1.1 Carcinogen induced bladder cancer in mice and rats 
In this model, the rodent is given a carcinogen, most commonly in the drinking water. BBN 
(N -butyl-N- (4-hydroxybutyl) nitrosamine) is a carcinogen given to the rodents in a 
concentration of 0.05% in the drinking water. It induces bladder tumors in 95% of the 
rodents after 25 weeks of administration (Okada et al., 1975). The tumors produced by the 
carcinogen resemble human bladder cancer in histology, etiology, and in kinetics (25 rat 
weeks equal 10 human years- the believed incubation period of human bladder cancer). 
Molecular events occurring during chemical carcinogenesis can be followed (Ariel et al., 
2004). Tumor development and the response to novel treatments can be assessed non-
invasively, without scarifying the animal using ultrasonography (Gofrit et al., 2006). The 
main disadvantages of this model are necessity to handle a carcinogen and the long period 
required for tumor production.  
In our lab we used this model to "fish up" genes involved in bladder tumorigenesis using 
microarray analyses. We identified both H19 and IGF2 among differentially expressed genes 
that are induced in response to carcinogen exposure (Elkin et al., 1998, Ariel et al., 2004) 
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 In the following sections we will present the role of both H19 and IGF2 genes in 
tumorigenicity. Then we will discuss pre-clinical and clinical data for the successful 
treatment of bladder cancer by DNA-based drug developed in our laboratory based on both 
the H19 and IGF2 regulatory sequences to drive the expression of a toxic protein, diphtheria 
toxin A (DT-A). This approach also proved to be successful in other cancer types; ovarian 
(Mizrahi et al., 2010), prostate (submitted) in human patients, and pre-clinically under 
development in glioblastoma (under preparation), lung (Hasenpusch et al., 2011), and 
colorectal liver metastasis (Ohana et al., 2005). This chapter will focus only on bladder 
cancer. Pre-clinical data using novel approaches for the treatment of bladder cancer with 
improved cytotoxic effect will be presented as well. 
2. The H19-IGF2 locus and tumorigenesis 
The IGF2 and H19 genes are both located on the short arm of chromosome 11 and are 
reciprocally imprinted. Genomic imprinting of the IGF2 and H19 genes has been shown to 
play a role in the regulation of the IGF2 and H19 expressions during embryonic 
development and in cancer. The role of genomic imprinting in tumor development is not 
well understood and it is beyond the scope of this chapter. Over-expressions of H19 and 
IGF2 genes in many tumors may or may not be associated with loss of imprinting. 
2.1 The pivotal role of H19 RNA in tumorigenesis 
H19 is an oncofetal gene that expresses only RNA and not protein, being expressed in the 
embryo, repressed in the adult, and re-expressed in a variety of human tumors, for review 
(Matouk et al., 2005). H19 is emerging as one of the key players in cancer biology.  We and 
others have demonstrated an essential role of H19 RNA in tumor development, and the 
association and contribution of H19 RNA with various aspects of tumorigenic process. This 
contradicts the initial proposal that H19 gene product has a tumor suppressive activity (Hao 
et al., 1993). 
Our strategy to delineate the role of H19 RNA in tumor development is based on 
determining if tumor development is dependent on H19 expression through both over-
expression and knockdown approaches in different tumor models including bladder cancer. 
To shed light into its mechanism of action our strategy is based on identifying upstream 
effectors and also downstream targets by applying the global gene expression profiling to 
identify genes modulated by both H19 over-expression and knockdown. Here again bladder 
cancer model is included.  
Our results, supported by results from others, reveal that H19 RNA harbors oncogenic 
properties, enhancing the development of carcinogenesis.  In this section we'll present major 
findings that support this issue and highlight its relevance to bladder cancer where possible. 
2.1.1 H19 RNA is essential for human tumor growth 
Although H19 over-expression sometimes associated with loss of imprinting have been 
reported in a large arrays of human cancers, direct evidence of its tumorigenic role was 
lacking. Using two cell line models including bladder carcinoma, we provided evidences, 
that H19 is critical for tumor development. Our in vivo results show that bladder carcinoma  
formed from UMUC3 cells in which the H19 RNA have been knocked down , induce a very 
significant retardation of tumor growth. Similar results were reproduced using other 
carcinoma model (Matouk et al., 2007). 
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Moreover we showed that ectopic H19 expression enhances the tumorigenic potential of 
bladder carcinoma cells in vivo. Tumors induced from T24P bladder carcinoma cell line 
ectopically over-expressing H19 RNA, differ significantly in their growth properties and 
growth kinetics in vivo relative to the control, and are well vascularized with evidences of 
tumor hemorrhage (Matouk et al., 2007). H19 RNA also enhances entry to S-phase of the 
cell cycle of bladder cancer cells under serum starved condition, but not under normal cell 
culture condition (Ayesh et al., 2002). Further supports for the tumorigenic properties 
have been reported in other cancer models. H19 over-expression of ectopic origin confers 
a proliferative advantage for breast epithelial cells in a soft agar assay and in several 
combined immunodeficient mice (Lottin et al., 2002). c-Myc induces the expression of the 
H19 RNA. c-Myc binds to the E-boxes near the imprinting control region to facilitate 
histone acetylation and transcriptional initiation of the H19 gene, to potentiate 
tumorigenesis (Barsyte-Lovejoy et al., 2006). The H19 is reported to be a target gene for 
the hepatocyte growth factor (HGF), further signifying the potential role of H19 RNA in 
hepatocellular carcinoma development (Adriaenssens et al, 2002). Furthermore, H19 RNA 
is important for entry into S-phase after serum starvation recovery by E2F binding to its 
promoter (Berteaux et al, 2005). Recently, it was reported that the Retinoblastoma tumor 
suppressor gene is a target gene for miR-675 which is produced from exon-1 of the H19 
gene (Tsang et al., 2010). 
2.1.2 H19 is induced by hypoxia – the P53 brakes and the HIF-1α engine 
It is well established that every solid tumor encounters hypoxic regions beyond certain 
diameters. Hypoxia is a major trigger for tumor angiogenesis, metastasis, chemo-resistance 
and also associated with poor prognosis at least in some types of human cancers. All of 
these conditions as discussed below are associated with an increase of H19 RNA expression. 
Over-expression of H19 RNA, is accompanied with up-regulation of a 95 kDa membrane 
glycoprotein (p95) observed in a variant of breast and lung carcinomas that are multi- drug 
resistance (Doyle et al., 1996). Moreover, results show that the level of H19 RNA is elevated 
in the multidrug resistance variant of HCC cell lines. Here doxorubicin resistance phenotype 
is related to H19 over-expression (Tsang et al., 2007). 
H19 provides a novel and clinically useful diagnostic marker for prognosticating human 
bladder carcinoma. More striking is the predictive value of H19 for tumor recurrence. We 
have found that in transitional cell carcinoma of the bladder with tumors that express H19 
in most cells have shorter median disease-free survivals (Ariel et al., 2000).  
We have identified downstream targets modulated by H19 over-expression in the T24P 
bladder carcinoma cell line (Ayesh et al., 2002); comparing the m-RNA levels of many genes 
between cells containing high levels of H19 RNA (from H19 expressing plasmid) to that of 
the same cells lacking H19 RNA, showed a clear preference towards genes promoting 
cellular migration, angiogenesis and metastasis.  
All of these observations prompted us to explore the effect of hypoxia on H19 expression 
and to delineate the mechanism of action involved. Indeed, under hypoxic conditions, we 
have reported that in bladder carcinoma cell lines T24P and UMUC3, and hepatocellular 
carcinoma cell line Hep3B the H19 RNA is significantly elevated (Matouk et al., 2007). 
Following these initial studies we screened about thirty different carcinomas cell lines of 
different lineages and origins for their ability to induce H19 RNA in hypoxic stress (Matouk 
et al., 2010). We observed very different patterns of response to hypoxia. To gain insight into 
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the possible mechanism associated with the H19 response to hypoxia, we searched for a 
common denominator among these cell lines. 
It is well established today that the tumor suppressor signaling pathway of p53 can be 
activated by stress signals such as hypoxic stress and can either trans-activate or trans-
repress its target genes to influence the cellular response. The key processes regulated by 
p53 pathway include cell cycle arrest, apoptosis, DNA repair, senescence, metastasis and 
angiogenesis, depending on cell types, nature of the inducer, cell intrinsic environment, and 
the activities of other signal transduction pathways. These observations suggests a possible 
association between the status of p53 (wild type or mutant) and H19 responsiveness to 
hypoxic stress. Moreover the involvement of the wild type tumor suppressor gene p53 in the 
down regulation of the H19 promoter activity which lacks a p53 consensus site and a TATA 
box was previously shown by (Dugimont et al., 1998). Taking all of these observations into 
account and the availability of IARC TP53 mutation database, we explored the possible 
involvement of p53 in determining H19's behavior in hypoxic response.   
We recently demonstrated a tight correlation between H19 RNA elevation by hypoxia and 
the status of the p53 tumor suppressor. In cells harboring wild type p53 (p53wt) H19 RNA is 
not induced upon hypoxia, whereas in cells carrying a mutated p53 (p53mt) the H19 message 
is significantly induced most strongly in p53-null cells. Furthermore through both over-
expression and knockdown approaches we identified HIF1-┙ as the factor that is responsible 
for H19 elevation under hypoxic stress (Matouk et al., 2010). 
H19 functions, consequently, as a stress modulator and a survival factor and is involved in 
several fundamental processes, including epithelial-mesenchymal transition (EMT), 
malignant transformation, cell-cycle transition, metastasis and neo-angiogenesis. EMT is an 
important process on the way to the malignant phenotype; notably- H19 up-regulation 
occurs in the stroma as well as in the epithelium. In the metastatic tumor stage, which bears 
a striking similarity to the embryonic stage, H19 involvement appears to be essential: 
adherent and cohesive cells lose their anchorage, migrate under stressful conditions to 
remote sites and replicate with neovascular support. Thus, H19 is a central figure in the 
cancer embryonic shift (Matouk et al., 2008).  
In the light of our study, a molecular mechanism that integrates H19, p53 and HIF1-┙ to 
hypoxic stress response is uncovered. As hypoxia readily occurs in the majority of solid 
tumors driving critical steps in tumor development and metastasis and resistance to 
therapeutic modalities, placing the H19 gene product in this deadly circuit undoubtedly will 
have major impacts in its utility as a target for cancer gene therapy. Indeed a DNA-based 
drug depending on H19 regulatory sequence and diphtheria toxin is now in clinical trial 
with promising results (Ohana et al., 2004, Sidi et al., 2008, Mizrahi et al., 2010). We'll 
concentrate on bladder cancer.    
2.1.3 Targetted therapy for bladder cancer mediated by a plasmid expressing DTA 
under the control of H19 regulatory sequences – clinical data 
During the past few years we have developed a DNA based therapy strategies for treating 
tumors expressing H19 RNA. The successful development of anti-tumor gene therapy 
depends on the use of a combinatorial approach aimed at targeted delivery and specific 
expression of effective anti-tumor agents. We exploit the unique H19 transcriptional 
regulatory sequences for directing tumor-selective expression of toxins. For this purpose we 
use non-viral vectors due to their potential to circumvent the main disadvantage of 
www.intechopen.com
 
The H19-IGF2 Role in Bladder Cancer Biology and DNA-Based Therapy 
 
369 
adenoviral vectors, caused by immune responses directed against adenovirus proteins 
which limit their ability to be administered iteratively. As a toxic gene, we used the 
diphtheria toxin A chain (DT-A), which has suitable properties for achieving efficacious 
cancer cell killing. DT-A peptide catalyzes ADP-ribosylation at the dipthamide residue of 
the cellular translation elongation factor 2 (eEF-2), inhibiting protein synthesis and causing 
cell death. While a very low level of DT-A expression suffices for cell killing, DT-A released 
from the lysed cells is not able to enter the neighboring cells in the absence of the DT-B 
chain.  
All preclinical studies needed to set up the stage for using this approach to treat bladder 
cancer patients will not be handled in this chapter, and are reviewed elsewhere (Matouk et 
al., 2005). 
Clinical studies 
The goals of treatment are to reduce tumor recurrence, decrease the risk of disease 
progression, avoid cystectomy (bladder sparing treatment), and improve survival. 
Preventing progression to muscle invasive disease is of key importance because even with 
aggressive treatment, including radical cystectomy, as few as 50% of patients with muscle 
invasive disease will survive 5 years (  Dalbagni et al., 2001). 
The primary factors that influence risk of disease progression include: 1. the number of 
tumors at primary diagnosis; 2. recurrence rate in a previous period or an early recurrence 
at 3 months after the first resection; 3. size of the tumor (tumors larger than 3 cm are more 
likely to recur than smaller tumors); and stage and grade of the tumor. 
The initial clinical development plan for DTA-H19/PEI for bladder cancer is in the 
intermediate-risk patient population who has failed prophylactic therapy with either BCG 
or chemotherapy. In the Phase 1/2a study, the safety and preliminary efficacy was 
examined in this population. Having determined that the highest dose tested in this trial, the 
20 mg dose of DTA-H19, was well tolerated and elicited complete responses in 2 of 5 
evaluable patients, the Phase 2b clinical protocol will assess the safety of this regimen in a 
larger patient population as well as the efficacy in a marker tumor clinical trial design. 
Compassionate Use in Bladder Cancer. Two patients had recurrent superficial TCC of the 
bladder and had failed multiple courses of Bacille Calmette-Guérin (BCG) and 
chemotherapy, and two additional patients that underwent nephrourectomy due to a 
diagnosis of recurrent superficial TCC that showed BCG intolerance. 
The investigations in the first two bladder cancer patients demonstrated that intravesical 
instillation of DTA-H19/PEI is safe up to a dose of 5 mg in a single administration or a 
cumulative dose of 70 mg intravesically. No local or systemic adverse effects considered 
attributable to DTA-H19 treatment were observed throughout treatment. In addition, DTA-
H19 DNA was not detectable in the circulation by PCR analysis of blood samples taken after 
the first and second week of treatment, and 2 hours after plasmid administration. DTA-H19 
DNA was detectable in a tumor biopsy taken 18 hours after intravesical administration and 
in voided urine for 1 week after treatment. Tumor regression (75% reduction in marker 
tumor size) was observed in marker tumors of both patients. One of the 2 compassionate 
patients was treated over a nearly 5 year period with 22 intravesical administrations of 
either a 2 mg or 4 mg dose of DTA-H19/PEI for a cumulative dose of 70 mg of plasmid 
DNA. Treatments were well tolerated, and although the marker tumor persisted, it did not 
increase in size, stage or grade during the 14-month period before it was finally resected 
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along with one other new low grade papillary tumor. No increase in stage or grade of TCC 
was observed. 
The patient that had a nephroureterectomy due to a diagnosis of high-grade TCC in the 
renal pelvis was treated with 6 weekly 10 mg injections of DTA-H19/PEI via the left 
nephrostome at a total volume of 15 ml each. After completion of the 6 plasmid infusions 
the patient underwent nephroscopy that revealed the following: renal pelvis with no 
presence of tumors and several papillary tumors on the left bladder wall in the trigon. 
Findings were biopsied, analyzed, and diagnosed as low grade TCC. Four months later, the 
patient underwent nephrography during which no tumors were observed. Urine cytology 
confirmed the absence of tumor cells.  
There were no significant events or side effects throughout the patient’s treatments. Overall, 
this was a good tumor response in a patient with only one kidney who was considered to be 
anephric and with dialysis during the last year. The treatment was well-tolerated by the 
patient, and there was no evidence of any negative systemic or urinary tract effect. During 
the treatments, the patient was fully functional, continued to work, and did not suffer any 
effect to his quality of life (QOL).  The second patient that had nephroureteterectomy had 
multiple recurrences with the appearance of multi-focal lesions in the bladder. The patient 
underwent additional resection of a number of lesions that were localized inside and on the 
walls of the bladder. Since the patient was not a candidate to receive BCG treatment due to 
his compromised immune system, and after being refractory to Mitomycin C or Synergo, 
and refusal to undergo cystectomy, he was offered treatment with DTA-H19/PEI. He was 
treated with 20 mg of DTA-H19/PEI twice a week for the period of 4 weeks and once a 
week for another 2 weeks. Cytoscopy conducted at the end of the treatment showed an 
improvement in the number of lesions and in the general appearance of the bladder. The 
histological diagnosis of the biopsy showed low grade Ta. 
Phase 1/2a Clinical Trial in Conventional Treatment Refractory Bladder Cancer Patients. A 
Phase 1/2a clinical trial was designed to determine the maximum tolerated dose (MTD) and 
assess the safety and preliminary efficacy of 5 different doses (2 mg, 4 mg, 6 mg, 12 mg, and 20 
mg of DTA-H19) of DTA-H19/PEI given as 6 intravesical infusions into the bladder of patients 
with superficial bladder cancer (stages Ta and carcinoma in situ (CIS)) who had failed 
intravesical therapy with BCG. Patients had a diagnosis of superficial Stage Ta or CIS, grade 1 
or 2 superficial bladder cancer that was confirmed by histopathology and that expressed H19 
which was shown by in situ hybridization (ISH). Treatments were given weekly for 3 weeks 
followed 1 week later by safety and disease assessments, then another 3 weekly instillations 
were performed. Each dose cohort received the same dose for all treatments. Doses were 
escalated if none of the first 3 patients in the preceding dose cohort experienced a dose-limiting 
toxicity (DLT) after the first 3 weekly intravesical treatments. A DLT was defined as any grade 
3 or greater toxicity by the National Cancer Institute Common Terminology Criteria for 
Adverse Events (NCI-CTCAE) that was considered to be related to the investigational product 
during the first 3 weekly intravesical treatments. Prior to initiating treatment, papillary tumors 
were resected leaving a single marker tumor. Videocystoscopy was performed 4, 8, and 12 
weeks after the start of treatment for a safety evaluation of the bladder and also to record the 
presence or absence of the marker tumor and any other lesions suspicious for TCC of the 
bladder. If the marker tumor was still present at the Week 12 assessment, it was to be resected. 
If any new lesions were observed at Week 12, they were also to be resected. Patients whose 
disease had not progressed (i.e., no new tumors, increase in the size of the marker tumor by at 
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least 50%, or increase in stage or any grade 3) were offered continued once monthly treatments 
and follow-up for up to 1 year.  
A total of 18 patients were enrolled in this study. No DLTs were observed in this study. As 
the highest dose of product tested was the 20 mg dose of DTA-H19/PEI, this dose was 
considered the MTD for this study. The most frequently reported adverse events (AEs) 
considered at least possibly related to investigational products for any dose cohort were 
mild to moderate in severity and were most commonly renal and urinary disorders.  
Of the 18 patients evaluable for tumor response at Week 12, a total of 4 patients had a 
complete response (CR) [complete disappearance of the marker tumor and no recurrence) 
including 2 of the 3 patients in the 2 mg dose cohort, and 2 of 6 patients in the 20 mg dose 
cohort. In addition, 2 patients (one in each of the 2 mg and 12 mg dose groups) had an 
incomplete partial response [IPR - complete disappearance of the marker tumor but with 
new tumor(s) occurring] suggesting that DTA-H19/PEI did have an effect on these marker 
tumors as well. Other responses included 1 partial response (PR - reduction in size of 
marker tumor by 50% and no new tumors present) (12 mg dose cohort) and 5 patients with 
SD (marker tumor still present but has not increased in size by more than 50% and no new 
tumors) (3 patients in the 4 mg dose cohort, 1 patient in the 12 mg dose cohort, and 1 patient 
in the 20 mg dose cohort). Thus, in this small study, there was evidence of tumor ablation 
over the dose range from 2 to 20 mg of DTA-H19/PEI. The 20 mg dose of DTA-H19/PEI 
was selected for evaluation in the Phase 2b clinical trial because this dose had an acceptable 
safety profile, showed objective tumor responses, and as the mechanism of action of DTA-
H19/PEI is tumor-specific cytotoxicity, theoretically the highest safe dose has the greatest 
likelihood of an efficacious outcome.  
2.2 Insulin-like growth factor 2 (IGF2) and tumorigenesis 
IGF2 expression is driven by four different promoters (P1-P4) that produce 4 different 
transcripts all of which give rise to the same mature protein, a 67-amino acid polypeptide. 
The four promoters are activated in a development-dependent and tissue-specific manner. 
In fetal liver, promoters P2–P4 are active, of which P3 is the most active promoter, and 
promoter P1 is inactive. However, in liver tissue, shortly after birth, the IGF2 promoter P1 is 
exclusively active. The imprinting of the human IGF2 gene is promoter-specific. The P2, P3 
and P4 promoters display monoallelic activity in embryonic, neonatal and postnatal liver 
specimens, whereas in adult, P1 is transcribed from both alleles. 
The IGF2 peptide is a member of the insulin-like growth-factor family and is known to play 
an important role in the growth and differentiation of various tissues (Rechler 1990). This 
family also includes IGF1, insulin and relaxin.  IGF2 is released to the extracellular fluid 
where it interacts with different cell membrane receptors and binding proteins. IGF2 binds 
three different types of receptors: IGF type 1 (IGF-1R), insulin receptor (IR) and IGF-
2/mannose 6-phospate receptors (IGF-2R/M6P). The receptors, however, differ completely 
in structure and function (Yu and Rohan 2000). Ligand binding to IGF-1R and IR mediates 
mitogenic and anti-apoptotic effects. IGF-2R/M6P has tumor suppressor function and it 
mediates IGF2 degradation (Morison and Reeve 1998, Randhawa and Cohen 2005).      
IGF2 can promote different functions depending on the cell type in which it is acting, and is 
a strong mitogen for a wide variety of cancer cell lines. It acts on the cell division cycle 
(DNA replication and mitosis) and on the cell growth (cellular enlargement), possibly by 
interfering with control cell checkpoint proteins. Moreover, IGF2 functions as an anti-
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apoptotic agent. For example, it blocks c-Myc and SV40 T-antigen induced apoptosis in Raf-
1 fibroblast cells (Ishii et al., 1993,  Morali et al.,  2000).  
The mitogenic and metabolic actions of IGF2 in embryonic development and tumorigenesis 
are mediated by the IGF-1R and/or IR-A and are tightly regulated at different levels. These 
levels include the IGF-receptors availability, IGF2 interaction with its receptors and binding 
proteins (IGFBPs) and its degradation following internalization of the IGF2 after binding to 
its receptor, especially IGF-2R. Moreover, the IGF2 mRNA and protein levels are regulated 
by different ways. Any abnormality at one or more of these levels can be correlated to 
tumorigenesis. Over-expression of growth factors, or their receptors is a common event in 
malignancy and provides the underlying mechanisms for one of the hallmarks of cancer, 
namely uncontrolled proliferation (Hanahan and Weinberg 2000).  
Transgenic mice, over-expressing the IGF2 gene, developed spontaneous tumors at a high 
frequency (Bates et al.,  1995, Moorehead et al.,  2003, Rogler et al.,  1994), suggesting that 
over-expressed IGF2 may be involved not only in the progression of tumors but also in the 
initiation of neoplasia. IGF2 over-expression is significantly correlated to the increased 
tumor progression and proliferative activity as well as to decreased patient survival 
(Kawamoto et al., 1998, Rogler et al., 1994, Takanami et al., 1996) 
Several mechanisms can potentially result in IGF2 over-expression in cancer, including, loss 
of imprinting (LOI) of the maternal allele, loss of heterozygosity (LOH) with paternal 
duplication, amplification of the IGF2 gene and abnormally activated signaling pathway 
leading to transcriptional up-regulation of the active alleles reviewed by (Hahn et al.,  2000). 
IGF2 imprinting is relaxed in many different types of tumors, including bladder cancer 
(Byun et al., 2007).  
The link between IGF2 and metastasis may be the basis for the identification of IGF2 and 
IGF-IR as predictors of poor outcome in many types of cancer.  
In the rat model of bladder cancer induced by BBN, we observed over-expression of igf2 in 
the tumor, relative to the low level of expression in the normal tissue (Ariel et al., 2004).  
Moreover we detected high levels of IGF2 mRNA expression from P3, P4 or both promoters 
in TCC samples. Whereas normal bladder samples showed no expression from either 
promoter. The human IGF2-P3 and IGF2-P4 promoters are highly active in bladder 
carcinoma. We showed that these constructs were able to selectively kill tumor cell lines and 
inhibit tumor growth in-vitro and in-vivo in accordance to the transcriptional activity of the 
above-mentioned regulatory sequences, when they are used to drive the expression of DTA 
(Ayesh et al., 2003, Amit et al., 2011).    
3. Double promoter vectors: Novel approaches for the treatment of bladder 
cancer with improved cytotoxic effect 
3.1 Double promoter DTA-expressing vectors 
We have shown that IGF2 or H19 are significantly expressed in 50-84% of human bladder 
carcinoma respectively (Elkin et al, 1995) but not in normal bladder. Whereas combined 
expression (e.g. H19 and IGF2-P3/P4) was detected at high levels in nearly 100% of human 
bladder cancer samples. By that proving that the double promoter vectors are suitable for 
treating all bladder cancer patients. P3 and P4 were able to express the DTA in tumor cells in 
vitro, and inhibited tumor growth of mice heterotopic model, proving that both promoters 
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could be used successively, in addition to H19 promoter, as part of the double promoter 
constructs (Ayesh et al., 2003, Amit et al., 2010, Amit et al., 2011). 
Double promoter expressing vectors were created, carrying on a single construct two 
separate DNA sequences expressing the diphtheria toxin A-fragment (DTA), from two 
different regulatory sequences, selected from cancer-specific promoters H19, IGF2-P3 and 
IGF2-P4. This novel approach, create a new family of plasmids regulated by two regulatory 
sequences, which in their natural genome position are both proximately located and are 
reciprocally imprinted.  
These vectors were then used to transfect and to eradicate tumor cells in culture or to inhibit 
tumor growth (in vivo), in heterotopic and orthotopic CD1 nude mice, bladder tumor 
models.  
The activity of the double promoter vectors was tested and compared to the activity of the 
single promoter vectors. The double promoter vectors exhibited superior activity compared 
to the single promoter vectors. Furthermore, an augmented-than-additive activity was 
exhibited, compared to combination activity of the single promoter vectors, in cell lines and 
in heterotopic bladder cancer mice (Amit et al., 2010, Amit et al., 2011).  
3.2 A single promoter driving two cytotoxic genes with synergistic effect 
Because it is unlikely that gene transfer reaches every cell of a cancer, DNA based therapy 
approaches are thought to require the induction of a ‘bystander’ effect. An interesting 
approach for this purpose is cytokine DNA based therapy. TNF- is a multifunctional and 
immuno-regulatory cytokine that exhibits direct tumor cell cytotoxicity, possesses anti-
angiogenic properties, and enhances antitumor immunity by activating immune cells such 
as dendritic cells and T cells. Systemic delivery of the TNF-┙ protein has had limited success 
clinically because of severe dose limiting toxic effects. This limitation can be overcome by 
the use of a gene delivery approach, combined with a tumor specific promoter to express 
TNF- in the tumor tissue. 
In this approach, an enhanced cytotoxic effect could be achieved that could also overcome 
the resistance developed by tumor cells to either one of the toxin. It was reported that 
several cell lines – none are bladder cancer- are resistant to Diphtheria toxin and therefore 
would not be affected by the pH19-DTA vector. Adding TNF-┙ to the existing system was in 
agreement with supporting evidence of some publications showing a synergistic effect in 
cell cytotoxicity mediated by TNF-┙ and diphtheria toxin. This was shown on ovarian 
cancer cell lines- sensitive or resistant to both diphtheria toxin and TNF-┙ and on renal cell 
carcinoma cell lines (Morimoto et al., 1991, Mizutani et al., 1994). Using a construct in which 
both TNF-┙ and DTA expressions are driven by H19 tumor specific promoter, would 
overcome the dose limiting toxic effects of the systemic delivery of TNF-┙ protein. 
So, we investigated a plasmid carrying, in addition to DTA, the gene for human hTNF-┙. 
The pH19-TNF-IRES-DTA plasmid was built while the construct carries a viral IRES 
sequence (from the ECMV virus) 3' of the TNF.  This IRES construct is 619 pb long and 
responsible the synthesis of DTA from the m-RNA transcript. 
3.2.1 Synergistic effect in the killing activity of DTA and TNF in vitro using different 
cell line models 
In vitro the cytotoxic effect in cells treated with the pH19-TNF-IRES-DTA plasmid was 
determined by luciferase assay (Ohana et al., 2004). To test for potency of this construct, cells 
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were also treated with a plasmid carrying either the DTA or TNF under the control of the 
H19 promoter. Cells from human, mouse and rat origin expressing H19 RNA were co-
transfected with 2 g/well of LucSV40 and the indicated concentrations of pH19-DTA, 
pH19-TNF or pH19-TNF-IRES-DTA plasmids. Luciferase activity was determined and 
compared to that of cells transfected with LucSV40 alone (Figure 1). In order to rule out the 
possibility of a false positive result due to the combined plasmid’s structure effect, we 
reversed the TNF sequence in the pH19-TNF-IRES-DTA plasmid to eliminate the expression 
of TNF (pH19-TNFrev-IRES-DTA). The killing potency of the pH19-TNF-IRES-DTA plasmid 
was significantly higher compared to the pH19-DTA plasmid alone, even at very low 
concentrations. As the concentrations got higher the difference was diminished (Figure 1). 
It should be noted that the use of the pH19-DTA plasmid alone was sufficient to cause a 
substantial decrease in luciferase activity, leading to 80-90% decrease in high concentrations, 
whereas the use of pH19-TNF alone showed little decrease, if any, and in some cases even an 
increase. When expressed in conjunction with the DTA domain, it clearly enhances cell death.  
 
 
Fig. 1. Enhanced killing activity of pH19-TNF-IRES-DTA vector in different bladder 
carcinoma cell lines. 
The killing potential of the pH19-DTA (blue), pH19-TNF (pink) or pH19-TNF-IRES-DTA(orange) 
vectors  in human UMUC-3 and HT-1376, mouse T-50 and rat NBT-II was measured as a reduction 
of luciferase activity induced by LucSV40. Cells were co-transfected with 2 g/well of LucSV40 and 
the indicated concentrations of pH19-DTA, or pH19-TNFα, or pH19-TNF-IRES-DTA. The pH19-
TNFrev-IRES-DTA(green) served as a control. 
3.2.2 In-vivo tumor growth inhibition by the pH19-DTA, pH19-TNF or pH19-TNF-IRES-
DTA vectors in a carcinogen rat bladder cancer model 
In vivo we utilize the carcinogen (BBN) induced rat bladder cancer model. Rats were treated 
with the above mentioned plasmids used in the in-vitro studies. An additional control 
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plasmid carrying the gene of Luciferase under the regulation of the H19 promoter (pH19-
Luc) was included.  
The therapeutic plasmid was given at two different times in order to investigate the 
correlation of the treatment efficiency to the severity and invasiveness of the disease. In the 
first, the plasmid treatments started after the rats received BBN for 20 weeks. By this time, 
the rats had developed visible tumors is their bladders. In the second, the plasmid treatment 
started only 16 weeks after the beginning of BBN administration in which tumors were 
visible only by histopathological examination. 
 
 
Fig. 2. Enhanced killing activity of pH19-TNF-IRES-DTA vector in the BBN rat bladder 
cancer model depending on time schedule of the treatments. 
Tumor index (volume X weight) of rat’s bladders as measured after treatment with three injections of 
pH19-DTA(green), pH19-TNF(brown) or pH19-TNF-IRES-DTA(red), and pH19-Luc(blue). A. 
Results of tumor index of rat’s bladders which started treatments after 20 weeks. B. Results of tumor 
index of rat’s bladders which started treatments after 16 weeks. 
Each rat, in both experiments and in each group, received intravesical injection of 50 µg of 
the plasmid administered 3 times with an interval of 3 days between treatments. Four days 
after the last treatment, all rats were sacrificed and bladders were removed, weighed, 
photographed, excised and taken either for histological analysis or for DNA/RNA 
preparation. Tumor index was derived as mentioned. Figure 2 shows the results of the in 
vivo experiments, where rats were treated from these two time points and onward. 
We decided to try and estimate the tumor’s volume by picturing each tumor at several 
angles, allowing us to use image analysis software in order to receive a reasonable 
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estimation. This was multiplied by the bladder’s weight in order to give us a new, more 
comprehensive index of the tumor’s status. It can be seen in the results that when starting 
the treatments after 20 weeks of BBN administration, virtually no effect is achieved in any of 
the plasmids. On the other hand, starting the treatments after 16 weeks showed a 
remarkable inhibition of tumor progression compared to the control. When administrated 
with pH19-DTA the tumor was delayed by approximately 30%, while when using the pH19-
TNF-IRES-DTA vector about 50% inhibition was measured. No effect was seen when pH19-
TNF was used. These results suggest that when treatment begins in an early stage it can be a 
highly potent one. 
4. Concluding remarks and future perspectives 
Our ability to understand the biology of bladder cancer at the molecular level utilizing the 
ever growing biotechnologies is an important step for understanding a wide range of 
signaling events in both healthy cells and in the context of carcinogenesis. Substantial 
progress has been made in this avenue. Many new genes that are involved in bladder 
carcinogenesis have been identified. It is clear the H19-IGF2 locus is playing a central role in 
this aspect. As the role of IGF2 in embryogenesis and tumorigenesis is relatively well 
understood, H19 as a stress modulator is recently emerging to be involved in several 
fundamental processes of tumorigenesis including that of the bladder.  Yet the exact 
molecular mechanisms that integrate H19 to such diverse events and circuits that are 
malfunctioning in cancer need further investigations. 
In our lab, different regulatory sequences, selected from cancer-specific promoters of  H19, 
IGF2-P3 and IGF2-P4 linked to the potent toxin (DTA),  have been successfully used to drive 
cytotoxicity  to cancer cells in vitro, in vivo, in different tumor models, and more 
importantly in bladder cancer patients, at least in the case of H19,  with promising results. 
Similar approaches are also used in other types of human cancers including ovarian, 
hepatocellular, and pancreatic cancers and are clinically encouraging. Preclinically, this 
approach also shows promising results in lung cancer, glioblastoma and colorectal cancer 
metastasis to the liver.  We are working on novel approaches to increase the cytotoxicity of 
the therapeutic plasmids, and to increase the numbers of patients that can benefit from this 
therapy. Furthermore, and given the central role of hypoxia and also p53 in the resistance of 
conventional therapeutic options and the involvement of the IGF2-H19 locus, we are 
developing sequential treatments of the therapeutic plasmids with conventional 
chemotherapeutic drugs with encouraging results. Moreover, the preclinical utility of short 
interfering RNA to knockdown both H19 and IGF2 is under development.  
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